232 related articles for article (PubMed ID: 15809928)
41. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients.
Drew RH; Dodds Ashley E; Benjamin DK; Duane Davis R; Palmer SM; Perfect JR
Transplantation; 2004 Jan; 77(2):232-7. PubMed ID: 14742987
[TBL] [Abstract][Full Text] [Related]
42. Delayed ABLC prophylaxis after allogeneic stem-cell transplantation.
Jansen J; Akard LP; Wack MF; Thompson JM; Dugan MJ; Leslie JK; Mattison R
Mycoses; 2006 Sep; 49(5):397-404. PubMed ID: 16922792
[TBL] [Abstract][Full Text] [Related]
43. Mortality rates in comparative trials of formulations of amphotericin B.
Frothingham R
Clin Infect Dis; 2001 Aug; 33(4):582-3. PubMed ID: 11462201
[No Abstract] [Full Text] [Related]
44. Pulmonary reactions during treatment with amphotericin B: review of published cases and guidelines for management.
Collazos J; Martínez E; Mayo J; Ibarra S
Clin Infect Dis; 2001 Oct; 33(7):E75-82. PubMed ID: 11528589
[TBL] [Abstract][Full Text] [Related]
45. Criteria for use of amphotericin B lipid complex injections in adults and children.
Am J Health Syst Pharm; 1996 Nov; 53(22):2751-2. PubMed ID: 9072180
[No Abstract] [Full Text] [Related]
46. Use of an amphotericin B lipid complex for treatment of blastomycosis in dogs.
Krawiec DR; McKiernan BC; Twardock AR; Swenson CE; Itkin RJ; Johnson LR; Kurowsky LK; Marks CA
J Am Vet Med Assoc; 1996 Dec; 209(12):2073-5. PubMed ID: 8960189
[TBL] [Abstract][Full Text] [Related]
47. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis.
Wingard JR; Kubilis P; Lee L; Yee G; White M; Walshe L; Bowden R; Anaissie E; Hiemenz J; Lister J
Clin Infect Dis; 1999 Dec; 29(6):1402-7. PubMed ID: 10585786
[TBL] [Abstract][Full Text] [Related]
48. Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis.
Walsh TJ; Whitcomb P; Piscitelli S; Figg WD; Hill S; Chanock SJ; Jarosinski P; Gupta R; Pizzo PA
Antimicrob Agents Chemother; 1997 Sep; 41(9):1944-8. PubMed ID: 9303390
[TBL] [Abstract][Full Text] [Related]
49. Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation.
Borro JM; Solé A; de la Torre M; Pastor A; Fernandez R; Saura A; Delgado M; Monte E; Gonzalez D
Transplant Proc; 2008 Nov; 40(9):3090-3. PubMed ID: 19010204
[TBL] [Abstract][Full Text] [Related]
50. Liposomal amphotericin B associated with severe hyperphosphatemia.
Sutherland SM; Hong DK; Balagtas J; Gutierrez K; Dvorak CC; Sarwal M
Pediatr Infect Dis J; 2008 Jan; 27(1):77-9. PubMed ID: 18162947
[TBL] [Abstract][Full Text] [Related]
51. Efficacy, safety and cost-effectiveness of Amphotericin B Lipid Complex (ABLC): a review of the literature.
Martino R
Curr Med Res Opin; 2004 Apr; 20(4):485-504. PubMed ID: 15119986
[TBL] [Abstract][Full Text] [Related]
52. Antifungals and renal safety--getting the balance right.
Saliba F
Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():21-4. PubMed ID: 16704922
[TBL] [Abstract][Full Text] [Related]
53. Reversible dilated cardiomyopathy related to amphotericin B therapy.
Danaher PJ; Cao MK; Anstead GM; Dolan MJ; DeWitt CC
J Antimicrob Chemother; 2004 Jan; 53(1):115-7. PubMed ID: 14657095
[TBL] [Abstract][Full Text] [Related]
54. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study.
Laguna F; Videla S; Jiménez-Mejías ME; Sirera G; Torre-Cisneros J; Ribera E; Prados D; Clotet B; Sust M; López-Vélez R; Alvar J;
J Antimicrob Chemother; 2003 Sep; 52(3):464-8. PubMed ID: 12888588
[TBL] [Abstract][Full Text] [Related]
55. Safety, tolerance and outcome of treatment with liposomal amphotericin B in paediatric patients with cancer or undergoing haematopoietic stem cell transplantation.
Kolve H; Ahlke E; Fegeler W; Ritter J; Jürgens H; Groll AH
J Antimicrob Chemother; 2009 Aug; 64(2):383-7. PubMed ID: 19491205
[TBL] [Abstract][Full Text] [Related]
56. [Liposomal amphotericin B in the treatment of severe fungal infections. Results of a clinical cohort trial].
Rieger CT; Dittmer M; Ostermann H
Dtsch Med Wochenschr; 2007 Oct; 132(40):2062-6. PubMed ID: 17899499
[TBL] [Abstract][Full Text] [Related]
57. Implementation of clinical practice policy on the continuous intravenous administration of amphotericin B deoxycholate.
Maharom P; Thamlikitkul V
J Med Assoc Thai; 2006 Nov; 89 Suppl 5():S118-24. PubMed ID: 17718252
[TBL] [Abstract][Full Text] [Related]
58. Retrospective analysis of the dosage of amphotericin B lipid complex for the treatment of invasive fungal infections.
Linden P; Lee L; Walsh TJ
Pharmacotherapy; 1999 Nov; 19(11):1261-8. PubMed ID: 10555932
[TBL] [Abstract][Full Text] [Related]
59. Should we continue using amphotericin B deoxycholate for the treatment of fungal infections? Adverse events and clinical outcomes.
Garbino J; Markham L; Matulionyte R; Rives V; Lew D
Scand J Infect Dis; 2006; 38(2):110-3. PubMed ID: 16449001
[TBL] [Abstract][Full Text] [Related]
60. Adverse drug reactions associated with the administration of amphotericin B lipid complex (Abelcet).
Cook G; Franklin IM
Bone Marrow Transplant; 1999 Jun; 23(12):1325-6. PubMed ID: 10414925
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]